Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

Completed · Phase 2

Conditions studied: Non-alcoholic Fatty Liver Disease

In brief

The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.

Key facts

Study ID
NCT06104319
Run by
GlaxoSmithKline
People needed
61
Starts
2024-01-22
Expected to finish
2025-09-23
Last updated by the study team
2025-10-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.